12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IDX719: Phase Ia started

Idenix began the Phase Ia portion of a U.S. Phase I trial of once-daily 5-100 mg IDX719. The Phase Ia portion will evaluate single doses of IDX719...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >